



ASX ANNOUNCEMENT

2 May 2016

Cynata Announces Japanese Patent Office Decision to Grant Patent for Cymerus™ MSC technology

Melbourne, Australia; 2 May 2016: Australian stem cell and regenerative medicine company, [Cynata Therapeutics Limited](#) (ASX: CYP), announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus™ mesenchymal stem cell (MSC) manufacturing technology.

The patent granted on Japanese Patent Application No. 2013-500186 entitled "Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions" will provide commercial rights in Japan through to 16 March 2031. This patent covers a proprietary method for deriving MSCs from pluripotent stem cells. Cynata has exclusive rights to this patent and to further patents and patent applications in respect of the Cymerus technology pursuant to a license agreement with the Wisconsin Alumni Research Foundation.

"Having an issued Japanese patent for our Cymerus technology is a critical step in the development and commercialisation of CYP-001, our first therapeutic MSC product," said Dr Ross Macdonald, CEO of Cynata. "The issued patent will protect this novel discovery and allow Cynata to further progress its commercial partnering activities in Japan, one of the leading markets for regenerative medicine and stem cells."

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, +1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleous@pcgadvisory.com
Rudi Michelson, Monsoon, Australia Media Contact, 0411 402 737, rudim@monsoon.com.au

About CYP-001

CYP-001 is Cynata's lead therapeutic product, an allogeneic, induced pluripotent stem cell (iPSC)-derived MSC. Cynata plans to undertake a Phase 1 clinical trial with CYP-001 in graft-versus-host disease (GvHD) before undertaking development for further disease targets, ideally in collaboration with commercial partners.

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Cynata Therapeutics Limited

Suite 1, 1233 High Street, Armadale, Victoria 3143, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com
ABN - 98 104 037 372